4 citations
,
November 2003 in “Annals of Plastic Surgery”
This study reports successful restoration of congenital pubic alopecia using tissue transfers from the temporoparietal scalp, noting significant hair growth in the transplanted tissue.
3 citations
,
October 2021 in “Indian Journal of Plastic Surgery”
This review discusses the evolution of follicular unit extraction techniques for hair transplant, highlighting various devices and methods but reports no clinical results; it emphasizes advancements in tools and techniques over the years.
January 2006 in “The Chinese Journal of Dermatovenereology”
This study reported that auto-hairgraft treatment for androgenetic and cicatricial alopecia showed high hair survival rates and patient satisfaction, with successful long-term outcomes.
2 citations
,
September 2013 in “Journal of Cosmetic Dermatology”
This review discusses advancements in managing male androgenetic alopecia, emphasizing long-term restoration techniques like follicular unit grafting combined with medical treatments, and reports no new experimental findings.
A user shared their experience with a LongHair DHI Hair Transplant, receiving 2,750 grafts. They plan to continue using Dutasteride and Topical Minoxidil post-surgery.
The user started taking dutasteride a month ago and is seeking advice on whether to wait for a year before getting a hair transplant, as it could potentially strengthen the donor-zone and require fewer grafts, or to get a transplant immediately, extracting only the "strong hairs" not affected by dutasteride. The user is unsure which approach is correct.
Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.
A 20-year-old is using minoxidil for hair regrowth and considering finasteride despite concerns about side effects. Many suggest adding finasteride to maintain gains, with recommendations to start with a low dose or use a topical form to minimize side effects.
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.